Recent Finacing
Recent Raise
Rondo Therapeutics develops a proprietary immuno-stimulatory platform to create bispecific antibody T‑cell engagers for solid tumors, advancing preclinical lead candidates toward Phase 1 clinical studies.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Rondo Therapeutics.
